Bing H. Wang, PhD, is a senior scientific director in the Analytical Science and Development Group of Sanofi. The current goal of Dr. Wang's research is to develop analytical methods that incorporate cutting-edge instrumentation and technologies to identify and quantify biomarkers for diseases. Through collaboration with scientists working on disease research, his team aims to facilitate the development of transformative therapies for diseases with unmet medical needs. Currently, Dr. Wang leads a team of scientists with in-depth training and experiences in mass spectrometry-based biomarker analysis. Over the years, Dr. Wang's group has developed expertise in sphingolipid analysis for various sample types such as cell pellets, solid tissues and biological fluids, including cerebrospinal fluid. His work has contributed to the development of Cerdelga, an approved oral therapy for Gaucher disease, and of other compounds currently in various stages of drug development.
Dr. Wang received his PhD in chemistry from Cornell University. He pursued post-doctoral work at the University of Muenster, Germany, and Massachusetts Institute of Technology prior to entering the biotech and pharma industries.